- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02069041
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Phase 1b Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Tainan, Taïwan, 70403
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Taipei, Taïwan, 10048
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Taoyuan City, Taïwan, 33305
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Histological or cytological diagnosis of hepatocellular carcinoma (HCC) or imaging findings consistent with HCC in a participant with liver cirrhosis and alpha-fetoprotein > 200 nanogram per milliliter
- At least 1 measurable or non-measurable lesion
- Child-Pugh A
- Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B not amenable to locoregional therapy or refractory to locoregional therapy
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Have not received previous systemic therapy for advanced HCC
- Have resolution to Grade ≤1 of all clinically significant toxic effects of prior locoregional therapy
- Adequate organ function including: Absolute neutrophil coun t≥1.5×109/liter (L), hemoglobin ≥9 gram/deciliter, and platelets ≥90×109/L; Total bilirubin level ≤1.5 the upper limit of the normal range (ULN), aspartate transaminase and alanine transaminase ≤5 ULN, albumin >28 gram/L; Serum creatinine level ≤1.5 ULN; or calculated serum creatinine clearance ≥50 milliliter/minute; International Normalized Ratio≤1.5 and partial thromboplastin time ≤5 seconds above ULN
- The urinary protein is ≤ 1+. If ≥ 2+ proteinuria, the 24-hour urine protein is <1000 milligram
- An estimated life expectancy of at least 12 weeks
Exclusion Criteria:
- Received any investigational therapy or non-approved drug within 28 days prior to enrollment
- Undergone major surgery within 28 days prior to enrollment, or undergone central venous access device placement within 7 days prior to enrollment
- Undergone hepatic locoregional therapy within 28 days prior to enrollment
- Undergone radiation to any nonhepatic site within 14 days prior to enrollment
- Prior liver transplant
- Fibrolamellar carcinoma or cholangiocellular carcinoma
- Received any transfusion, blood component preparation, erythropoietin, albumin preparation, or granulocyte-colony stimulating factors within 14 days prior to enrollment
- Receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents
- Receiving ongoing therapy with nonsteroidal anti-inflammatory agents or other antiplatelet agents.
- Known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness
- Active or uncontrolled clinically serious infection
- Uncontrolled thrombotic or hemorrhagic disorder
- Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
- History of gastrointestinal perforation or obstruction
- History of or current hepatic encephalopathy or current clinically meaningful ascites
- Known allergy to monoclonal antibody, fluorouracil, oxaliplatin or their excipients
- Interstitial pneumonia or interstitial fibrosis of the lung
- Central nervous system metastases or carcinomatous meningitis
- Known history of dihydropyrimidine dehydrogenase deficiency
- Symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia
- Experienced any arterial thromboembolic event
- Uncontrolled arterial hypertension
- Grade 3-4 venous thromboembolic events occurring within 3 months prior to enrollment
- Experienced any grade 3-4 gastrointestinal bleeding or any variceal bleeding episode in the 3 months prior to enrollment requiring transfusion, endoscopic or operative intervention
- Esophageal or gastric varices that require immediate intervention or represent a high bleeding risk
- Pre-existing grade ≥ 2 motor or sensory neuropathy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Ramucirumab + FOLFOX4
8 milligram/kilogram (mg/kg) ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles: FOLFOX4 every 2 weeks: 85 milligram per square meter (mg/m²) oxaliplatin IV on Day 1 200 mg/m² folinic acid(FA) IV on days 1 and 2 400 mg/m² 5-FU bolus on days 1 and 2 600 mg/m2 5-FU 22-h continuous infusion on Days 1 and 2 Participants may continue to receive treatment until discontinuation criteria are met. |
Administré IV.
Autres noms:
Administered IV.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Délai: Baseline through study completion (Up To 8 Months)
|
A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.
|
Baseline through study completion (Up To 8 Months)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab
Délai: Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours
|
Maximum Concentration (Cmax)
|
Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours
|
PK:Area Under the Concentration-Time Curve (AUC[0-∞]) of Ramucirumab
Délai: Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours
|
Area under the concentration-time curve.
|
Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours
|
Number of Participants With Anti-Ramucirumab Antibodies
Délai: Baseline through 6.1 Months
|
Baseline through 6.1 Months
|
|
Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
Délai: Response to Disease Progression or Death (Up To 7 Months)
|
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version[v] 1.1) criteria.CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size [<10 millimeter (mm) short axis]. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease(PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest).In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Percentage of participants with CR or PR= (number of participants whose best overall response was CR or PR)/(number of participants treated)*100. |
Response to Disease Progression or Death (Up To 7 Months)
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Tumeurs par type histologique
- Tumeurs
- Tumeurs par site
- Adénocarcinome
- Tumeurs, glandulaires et épithéliales
- Tumeurs du système digestif
- Maladies du foie
- Tumeurs du foie
- Carcinome
- Carcinome hépatocellulaire
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents protecteurs
- Micronutriments
- Vitamines
- Antidotes
- Complexe de vitamine B
- Fluorouracile
- Oxaliplatine
- Leucovorine
- Ramucirumab
Autres numéros d'identification d'étude
- 15233
- I4T-CR-JVCQ (Autre identifiant: Eli Lilly and Company)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Ramucirumab
-
Shanghai Henlius BiotechRésiliéVolontaires masculins en bonne santéChine
-
Yonsei UniversityPas encore de recrutementCancer de l'estomac | Cancer de la jonction gastro-oesophagienne (JGE)
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.ComplétéCancer de l'estomac | Cancer du poumon non à petites cellules | Cancer colorectalChine
-
Eli Lilly and CompanyParexelComplétéTumeurs solides avancéesJapon
-
Yale UniversityRetiréCarcinome à cellules transitionnellesÉtats-Unis
-
Eli Lilly and CompanyComplétéEn bonne santéÉtats-Unis
-
Eli Lilly and CompanyComplété
-
Samsung Medical CenterRecrutementCancer de l'estomacCorée, République de
-
Eli Lilly and CompanyComplétéCarcinome hépatocellulaireÉtats-Unis, Canada, Belgique, Allemagne, Israël, Corée, République de, Espagne, Australie, L'Autriche, Brésil, France, Italie, Japon, Le Portugal, Taïwan, Roumanie, Bulgarie, République tchèque, Finlande, Hong Kong, Hongrie, Pays-Bas, Norvè... et plus
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Eli Lilly and CompanyComplétéGlioblastome Multiforme AdulteÉtats-Unis